XML 44 R30.htm IDEA: XBRL DOCUMENT v3.20.4

Revenues (Tables)

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue

Revenues were as follows:

						Year Ended December 31, 2020																								Year Ended December 31, 2019																								Year Ended December 31, 2018
(in millions)						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total
Product Sales:
HIV Products
Atripla						$	307					$	21					$	21					$	349					$	501					$	60					$	39					$	600					$	967					$	131					$	108					$	1,206
Biktarvy						6,095						735						429						7,259						4,225						370						143						4,738						1,144						39						1						1,184
Complera/Eviplera						89						159						21						269						160						214						32						406						276						327						50						653
Descovy						1,526						197						138						1,861						1,078						255						167						1,500						1,217						308						56						1,581
Genvoya						2,605						490						243						3,338						2,984						664						283						3,931						3,631						794						199						4,624
Odefsey						1,172						450						50						1,672						1,180						438						37						1,655						1,242						335						21						1,598
Stribild						125						54						17						196						268						75						26						369						505						97						42						644
Truvada						1,376						27						45						1,448						2,640						101						72						2,813						2,605						260						132						2,997
Other HIV (1)						25						5						28						58						30						5						12						47						40						7						14						61
Revenue share - Symtuza (2)						331						149						8						488						249						130						—						379						27						52						—						79
Total HIV product sales						13,651						2,287						1,000						16,938						13,315						2,312						811						16,438						11,654						2,350						623						14,627
Hepatitis C virus (“HCV”) Products
Ledipasvir/Sofosbuvir (3)						92						29						151						272						312						71						260						643						802						144						276						1,222
Sofosbuvir/Velpatasvir (4)						864						337						398						1,599						971						553						441						1,965						934						654						378						1,966
Other HCV (5)						132						48						13						193						182						118						28						328						287						98						113						498
Total HCV product sales						1,088						414						562						2,064						1,465						742						729						2,936						2,023						896						767						3,686
Veklury						2,026						607						178						2,811						—						—						—						—						—						—						—						—
Cell Therapy Products
Yescarta						362						191						10						563						373						83						—						456						263						1						—						264
Tecartus						34						10						—						44						—						—						—						—						—						—						—						—
Total Cell Therapy product sales						396						201						10						607						373						83						—						456						263						1						—						264
Trodelvy						49						—						—						49						—						—						—						—						—						—						—						—
Other Products
AmBisome						61						230						145						436						37						234						136						407						46						229						145						420
Letairis						314						—						—						314						618						—						—						618						943						—						—						943
Ranexa						9						—						—						9						216						—						—						216						758						—						—						758
Vemlidy						356						29						272						657						309						21						158						488						245						12						64						321
Viread						14						34						137						185						32						69						142						243						50						82						175						307
Zydelig						31						39						2						72						47						54						2						103						61						70						2						133
Other (6)						146						53						14						213						153						52						9						214						154						56						8						218
Total Other product sales						931						385						570						1,886						1,412						430						447						2,289						2,257						449						394						3,100
Total product sales						18,141						3,894						2,320						24,355						16,565						3,567						1,987						22,119						16,197						3,696						1,784						21,677
Royalty, contract and other revenues						76						241						17						334						80						244						6						330						72						310						68						450
Total revenues						$	18,217					$	4,135					$	2,337					$	24,689					$	16,645					$	3,811					$	1,993					$	22,449					$	16,269					$	4,006					$	1,852					$	22,127

_______________________________

(1)     Includes Emtriva and Tybost.

(2)     Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(3)     Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4)     Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5)     Includes Vosevi and Sovaldi.

(6)     Includes Cayston, Hepsera and Jyseleca.

Summarized revenues from major customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:

						Year Ended December 31,
(as a percentage of total revenues)						2020						2019						2018
AmerisourceBergen Corporation						27		%				21		%				20		%
Cardinal Health, Inc.						21		%				21		%				21		%
McKesson Corporation						20		%				22		%				21		%

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration